CCR4 and pulmonary fibrosis: The study showed that CCL17 is a pro-fibrotic mediator of lung fibroblasts, suggesting that CCL17 or CCR4 inhibition may serve as an effective strategy to suppress lung fibroblast activation and attenuate pulmonary fibrosis progression [132].